Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Equillium Inc EQ

Healthcare Biotechnology
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as... see more

Current News (NDAQ:EQ)

Equillium to Participate in Upcoming Investor Conferences

GlobeNewswire November 20, 2025

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

GlobeNewswire November 13, 2025

Equillium to Participate in Upcoming Investor Conferences

GlobeNewswire November 4, 2025

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 3, 2025

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

GlobeNewswire October 22, 2025

Equillium Announces Leadership and Corporate Updates

GlobeNewswire October 6, 2025

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 3, 2025

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Business Wire August 29, 2025

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Business Wire August 11, 2025
View More News ››

Opinion & Analysis (NDAQ:EQ)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:EQ)

Strong Hold!

HUGE news! New partnership with Ono, a leading Japanese pharmaceutical company to further itolizumab!! the potential of itolizumab is...
Shanemorg58 - December 6, 2022

RE:RE:Bang zoom

JohnTool321 - August 5, 2022

RE:RE:Bang zoom

SusanBolland - July 11, 2022

RE:RE:Bang zoom

Lisagerrard17 - July 8, 2022

RE:RE:Bang zoom

Those T cells can be tricky.
Joe455 - May 30, 2022

RE:Bang zoom

GassXX - May 29, 2022
View more Bullboard ››

Sky Gold Corp.

Sky Gold Corp.

Sky Gold Corp., a junior mineral exploration company, engages in the exploration and development of mineral properties in ...
View More »